MARKET NOTES / 001UNITED STATES / SEATTLE / INFECTIOUS DISEASES
LESS GUESSWORK. A BETTER RESEARCH LIST.

Infectious Diseases.
Seattle.

Map the capital.
Find your next conversation.

Who backs this market, where they enter, and how recently they have added a new company. A directory built around the questions founders actually ask.

Build your research shortlist ↘
Companies are based in Seattle · investors can be based anywhere
Dataset through 22 May 2026 · calculated 14 Sep 2026
01 / THE SHORTLIST LAB

Make the list work for your company.

No local headquarters are recorded for this shortlist. Browse 11 backers from all locations. Compare up to three.

0 of 11 selected backers · Seattle only

Shows investors whose recorded city is Seattle. Unknown cities are excluded. Market charts cover all investor locations.

Theme filtering selects backers of companies carrying that theme tag. Entry-stage filtering selects backers with an entry at that stage; the two matches may be different companies. Row metrics describe their entire dated Infectious Diseases history in Seattle.

Selected investors ranked by distinct companies backed, with first-entry financing and recent activity.
CompareInvestor / recorded locationCompanies
here
New in
24 months
Median total
entry round
Companies
backed again
Latest
investment
Loading investors…
THE INVESTOR, IN CONTEXT
LINKEDIN ACCESS

Continue with Radar

Sign in to Radar to continue researching this investor.

Sign in to Radar ↗
02 / THE MARKET READ

Activity is a better starting point
than a long list of names.

Latest 24 months: after 22 May 2024 through 22 May 2026.

RECENT PARTICIPATION
8

Backers in a recent round

5 added at least one new company in this market. The remainder participated only in companies they had already backed here.

Explore recently active backers ↗
MARKET PACE
1

Distinct equity rounds

Across 1 companies, versus 2 rounds in the preceding 24 months. Each company round is counted once.

See the recent evidence ↗
EARLY FINANCING
0%

Rounds at Angel, Pre-Seed or Seed

0 of 1 recent rounds. Compare your stage with its own financing range before sizing the ask.

Compare stage ranges ↗
NEW RELATIONSHIPS
63%

Participations were first entries

5 first investor–company relationships out of 8 participations. The other 3 were later rounds together.

Find backers adding companies ↗

Build a syndicate beyond the city.

Of 8 recently active backers, 0 have a recorded Seattle location and 8 are based elsewhere. Location is missing for 0. Search by market experience first, then investigate the people and their remit.

Match the whole round to your plan.

Recent Seed rounds have a median size of Undisclosed, across 0 disclosed amounts. That is total company financing. An individual investor’s cheque or available capital is not disclosed here.

03 / EMERGING THEMES

Which themes are gaining share?

Follow financing activity across the company classifications represented in this market.

Latest four complete quarters: 01 Apr 2025–31 Mar 2026 · 0 market rounds, versus 1 in the preceding four quarters.

INSUFFICIENT RECENT HISTORY

Biopharmaceuticals

Insufficient history

0 of 0 recent rounds (—%), versus 1 of 1 (100.0%).

INSUFFICIENT RECENT HISTORY

Oncology

Insufficient history

0 of 0 recent rounds (—%), versus 0 of 1 (0.0%).

INSUFFICIENT RECENT HISTORY

Immunotherapy

Insufficient history

0 of 0 recent rounds (—%), versus 1 of 1 (100.0%).

INSUFFICIENT RECENT HISTORY

In Vitro Diagnostics

Insufficient history

0 of 0 recent rounds (—%), versus 0 of 1 (0.0%).

SPIKE DETECTION

Look beyond the headline total.

Share of market roundsPrior four-quarter shareDetected spike

Scroll sideways to explore all quarters.

Biopharmaceuticals: quarterly share of recorded equity roundsSolid line: share of market rounds. Dashed line: share over the previous four complete quarters. Rings mark rule-based spikes. Shading marks a partial quarter, excluded from detection. 0%25%50%75%100% Partial 2020Q3 2020: 1 / 1 rounds, 100%Q4 2020: 1 / 1 rounds, 100%2021Q2 2021: 1 / 1 rounds, 100%Q4 2021: 1 / 1 rounds, 100%2022Q1 2022: 1 / 1 rounds, 100%Q4 2022: 1 / 1 rounds, 100%2023Q1 2023: 1 / 1 rounds, 100%20242025Q1 2025: 1 / 1 rounds, 100%2026

Q1 2026 · 0 of 0 market rounds · 0 companies · —% share. No spike under the published rule.

Select a dot to inspect the exact count and baseline. The partial quarter through 22 May 2026 is shown but cannot trigger a spike.

The theme shift, year by year.

Share of all recorded Infectious Diseases rounds in Seattle. Each cell also gives its theme-round count.

Theme shares and round counts by calendar year. 2026 is partial through 22 May 2026.
Investment theme2020202120222023202420252026*
100.0%2 / 2100.0%2 / 2100.0%2 / 2100.0%1 / 1—0 / 0100.0%1 / 1—0 / 0
50.0%1 / 20.0%0 / 20.0%0 / 20.0%0 / 1—0 / 00.0%0 / 1—0 / 0
50.0%1 / 20.0%0 / 2100.0%2 / 20.0%0 / 1—0 / 0100.0%1 / 1—0 / 0
0.0%0 / 20.0%0 / 20.0%0 / 20.0%0 / 1—0 / 00.0%0 / 1—0 / 0
0.0%0 / 20.0%0 / 20.0%0 / 20.0%0 / 1—0 / 00.0%0 / 1—0 / 0
0.0%0 / 20.0%0 / 20.0%0 / 20.0%0 / 1—0 / 00.0%0 / 1—0 / 0

*2026 is partial. Company themes use the tags available in this dataset, applied to historical rounds; they do not date when a business adopted a technology. Themes overlap, so shares do not add to 100%. Each company round is counted once within a theme. These charts cover investors from all locations; the shortlist keeps its own location filter.

How a spike is detected

A complete quarter is flagged when its theme share is at least 1.75× the share across the preceding four quarters and at least 5 percentage points higher. It must contain at least 3 theme rounds across 3 companies, at least 10 market rounds, and at least 3 theme rounds in the baseline. All four baseline quarters must have market observations. A zero baseline, missing observations or partial quarter cannot produce a flag.

This is a transparent screening rule, not a statistical significance test or a forecast. A higher share can accompany fewer rounds when the wider market contracts; the counts beside the chart make that distinction visible.

04 / THE DEPTH MAP

One appearance, or a pattern?

57 of 63 backers with dated histories appear in just one company. Select a cell to explore the directory.

Backers by type and number of distinct Infectious Diseases companies backed in Seattle, all dated history.
Portfolio breadth here1 company2 companies3–56–1011+
Firms & institutions
Individual angels

Circle area increases with backer count. The shortlist includes backers with 2 or more companies in this market, plus other backers active in the latest 24 months. In the 1-company cell, only recently active backers are available to explore. The shortlist’s investor-location filter also applies; select all locations to broaden the results. 0 backers have only undated entries.

05 / ROUND DESIGN

Different stages. Different capital.

Recent equity rounds · 24-month window.
Amounts are in USD.

StageDistinct roundsMedian / middle half
Series B
1
$110M$110M–$110M1 disclosed · small sample
06 / FOLLOW THE EVIDENCE

The most recent recorded rounds.

Distinct company rounds.
Named backers are shown lead-first.

Series B

Developer of vaccines for the treatment of various diseases

$110M total equity round
8 named backers

Medicxi · Adjuvant Capital · GC Biopharma · HBM Healthcare Investments · Janus Henderson Investors · +3 more

Series B

Developer of cell and gene therapy by using the epigenomic platform

$182M total equity round
4 named backers

New Enterprise Associates · Hevolution · Regeneron Ventures · Yosemite

Series A

Developer of vaccines for the treatment of various diseases

$26M total equity round
4 named backers

Adjuvant Capital · Green Cross · Janus Henderson Investors · RA Capital Management

Series A

Developer of vaccines for the treatment of various diseases

$60M total equity round
5 named backers

RA Capital Management · Adjuvant Capital · E&Investment · Green Cross · Janus Henderson Investors

Series A

Developer of cell and gene therapy by using the epigenomic platform

$40M total equity round
4 named backers

Emerson Collective · New Enterprise Associates · Hatteras Venture Partners · Mission BioCapital

Series B

Developer of computationally designed VLP vaccines for treating multiple infections

$100M total equity round
11 named backers

RA Capital Management · Adams Street Partners · Citadel · Cormorant Asset Management · Janus Henderson Investors · +6 more

07 / READING THE ATLAS

What these patterns can tell you.

The market boundary

Recorded equity rounds for companies tagged Infectious Diseases and located in Seattle. Investor headquarters may be elsewhere. Company sector and location reflect the available company records, not necessarily the location or sector at the investment date.

The time boundary

Data coverage ends 22 May 2026. The latest market round is 06 Mar 2025. There are 0 undated participations, excluded from timing metrics. Activity after the cutoff is unknown.

The relationship boundary

“New” is the first dated relationship between a backer and a company in this market. “Backed again” requires a later dated round together. A first observed entry may follow an earlier unrecorded investment.

The financing boundary

Amounts describe entire equity rounds, not personal cheques, fund capacity or returns. Medians exclude missing and non-positive amounts; the middle half spans the 25th–75th percentiles. A recorded investment does not establish current availability.

RADAR / COMPANY DISCOVERY

Find the businesses
worth a closer look.

Search Seattle Infectious Diseases companies in Radar. Filter the company directory to explore the businesses behind your market and investor research.

Explore companies in Radar ↗
FLIAR / CUSTOM DASHBOARD SERVICE

A research dashboard.
Built for your company.

We build customized research dashboards for companies. Tell us which competitors, markets and questions matter to your team, and discuss a dashboard designed around your needs.

Discuss a custom dashboard ↗A customized service from Fliar. Contact us to discuss your requirements.
FLIAR PRISM / RESEARCH TOOL

Turn your questions
into deeper research.

Use Fliar Prism to research a company, market or topic, with reports and insights drawn from its research dataset.

Explore Fliar Prism ↗Start with the company or question you want to understand.

Calculated 14 Sep 2026 · 11 investor histories to explore